title: Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group).
abstract: BACKGROUND
  There is no established therapy for maintaining remission in patients with Crohn's disease. Following different suggestions from the literature, two potential interventions for maintaining remission were tested against placebo, using either 5 g/day of a highly concentrated omega-3 fatty acid compound or a carbohydrate-reduced diet (84 g/day).
  
  
  METHODS
  A total of 204 patients were recruited after they had had an acute relapse. After remission (CDAI < or = 150) was attained with steroid therapy, patients were randomized to receive either omega-3 fatty acids (n = 70), placebo (n = 65), or diet (n = 69). Low-dose prednisolone was given to all patients for the first 8 weeks of intervention. CDAI and an acute-phase protein (CRP) were used as criteria for a relapse.
  
  
  RESULTS
  The proportion of patients without relapse within a year were similar in the placebo and active treatment group (intention-to-treat analysis: placebo, 30%; active treatment, 30%; protocol-adhering patients, 29% versus 28%). Patients did gain benefit (53%; p = 0.023) for as long as they maintained the diet. However, intention-to-treat analysis (diet group, 40%) did not show a noticeable difference when compared with placebo.
  
  
  CONCLUSIONS
  Omega-3 fatty acids did not show an effect on extending the remission in Crohn's disease. For the diet patients the question remains whether the noncompliant patients dropped out early because they sensed a relapse approaching or whether their condition deteriorated because they failed to comply with the diet.
authors.affiliation: Med. Klinik I, Städt. Krankenhaus, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Lorenz-Meyer
authors.forename: P
authors.initials: P
authors.lastname: Bauer
authors.forename: C
authors.initials: C
authors.lastname: Nicolay
authors.forename: B
authors.initials: B
authors.lastname: Schulz
authors.forename: J
authors.initials: J
authors.lastname: Purrmann
authors.forename: W E
authors.initials: WE
authors.lastname: Fleig
authors.forename: C
authors.initials: C
authors.lastname: Scheurlen
authors.forename: I
authors.initials: I
authors.lastname: Koop
authors.forename: V
authors.initials: V
authors.lastname: Pudel
authors.forename: L
authors.initials: L
authors.lastname: Carr
mesh_terms: D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000178:diet therapy* / Q000188:drug therapy; D004040:Dietary Carbohydrates / Q000008:administration & dosage; D004311:Double-Blind Method; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011239:Prednisolone / Q000627:therapeutic use; D012074:Remission Induction; D013223:Statistics as Topic
chemical_list: D000893:Anti-Inflammatory Agents; D004040:Dietary Carbohydrates; D015525:Fatty Acids, Omega-3; D011239:Prednisolone